Event ·Multi-source

OpenAI 收购 Orchestra Bio，用智能体加速药物研发

OpenAI 收购初创公司 Orchestra Bio，并计划将其并入旗下生命科学 AI 平台 Rosalind。合并后的目标是构建 AI 智能体，帮助制药团队协调药物开发流程，包括跟踪临床试验和发现问题。目前在美国研发一款新药平均需要 10 到 15 年。OpenAI 此前已与 Novo Nordisk 和 Moderna 在 AI 驱动的制药研究上展开合作。

Current read

OpenAI 收购 Orchestra Bio，要和自家 Rosalind 平台合并做药物研发智能体，Novo Nordisk 和 Moderna 已经在用它的方案了。

11 sources72° AI heatLast updated 2026/10/21 08:32:54

Evidence

11 sources

Primary sourceDecoder

2026/10/21 08:32:54View source

Related source 1IT之家

2026/10/20 22:51:11View source

Related source 2OpenAI

2026/10/20 18:10:16View source

Related source 3rohanpaul_ai

2026/10/20 18:58:27View source

Related source 4kimmonismus

2026/10/20 21:21:35View source

Related source 5TestingCatalog

2026/10/20 18:21:43View source

Related source 6Mark Chen (OpenAI 研究)

2026/10/20 19:33:08View source

Related source 7techcrunch

2026/10/20 20:35:10View source

Related source 8Tech in Asia

2026/10/21 06:21:20View source

Related source 9@koltregaskes

2026/10/19 14:28:00View source

Related source 10@OpenAIDevs

2026/10/19 18:01:27View source

Conflict check

Dedup data only shows that these sources discuss the same event, not that they agree. There is no structured supporting or refuting evidence yet, so no conflict is inferred automatically.

Open the story